Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Impact of SOLO-1 on Advanced Ovarian Cancer Management

April 29th 2019

Advanced OC: Interpreting the Design and Results of SOLO-1

April 29th 2019

PARP Inhibitor Selection in Advanced OC

April 29th 2019

Recurrent Ovarian Cancer: PARP Inhibitor Maintenance Therapy

April 29th 2019

Advanced OC: Clinical Data Behind PARP Inhibition

April 29th 2019

Evolution of PARP Inhibitors in Advanced Ovarian Cancer

April 29th 2019

Comprehensive Review of Maintenance Therapy in Advanced OC

April 29th 2019

Frontline Therapy and Recurrence in Advanced Ovarian Cancer

April 29th 2019

Recommended Approaches to Treating Advanced Ovarian Cancer

April 29th 2019

Advanced Ovarian Cancer: Role of Non-BRCA Mutations

April 29th 2019

Optimizing BRCA Testing in Advanced Ovarian Cancer

April 29th 2019

Role of BRCA Mutations in Advanced Ovarian Cancer

April 29th 2019

Advanced Ovarian Cancer: Evaluating Prognoses

April 29th 2019

EU Panel Backs Olaparib Approval for Frontline Maintenance in Ovarian Cancer

April 29th 2019

The European Committee for Medicinal Products for Human Use has recommended approval of olaparib as a frontline maintenance treatment for patients with BRCA-mutant advanced high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response following first-line platinum-based chemotherapy.

Folate Receptor Alpha as a Therapeutic Target for Ovarian Cancer

April 19th 2019

Investigational data are associated with folate receptor alpha-targeting agents, with an emphasis on the recent development and therapeutic potential of antibody-drug conjugates for the treatment of patients with ovarian cancer.

Moore Assesses Potential Impact of Antibody-Drug Conjugates in Ovarian Cancer Treatment

April 18th 2019

Kathleen N. Moore, MD, discusses the potential impact of antibody-drug conjugates on outcomes for patients with ovarian cancer.

Birrer Shares Perspective on Folate Receptor Alpha-Targeting Agents in Ovarian Cancer

April 18th 2019

Michael Birrer, MD, PhD, discusses the evolution of folate receptor alpha-targeting agents in ovarian cancer.

Evaluating the Role of Folate Receptor Alpha Expression in Ovarian Cancer

April 17th 2019

Multiple agents that target folate receptor alpha have been developed and are currently under investigation for the treatment of patients with ovarian cancer.

Dr. Liu on PARP Inhibitors in Recurrent Ovarian Cancer

April 16th 2019

Joyce F. Liu, MD, MPH, assistant professor of medicine, Harvard Medical School, and director of clinical research for gynecologic oncology at Dana-Farber Cancer Institute, discusses the use of PARP inhibitors in patients with recurrent ovarian cancer.

Frontline Maintenance Efforts Evolve in Advanced Ovarian Cancer

April 11th 2019

Although there are several maintenance strategies to consider for patients with advanced ovarian cancer, the decision of which approach to pursue largely depends on the molecular makeup of an individual patient’s tumor.